Phaseline

Targets › VEGFA

VEGFA (Vascular endothelial growth factor A, long form): drug programs, companies and trials

54 programs from 45 companies in 349 trials: 195 Phase 2, 83 Phase 3, 50 Phase 1, 21 Phase 4; Oncology, Ophthalmology, Metabolic and endocrine; next expected readout Dec 2026.

[N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death (By similarity)..; FUNCTION: [VEGFA]: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces…. (UniProt, P15692)

Open in Phaseline: the race on VEGFA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheFaricimab
Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor
ANGPT2, VEGFAPhase 4Diabetic Macular EdemaJan 2027
Amur State Medical AcademyDeoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)
VEGF gene therapy - plasmid DNA encoding vascular endothelial growth factor 165
VEGFAPhase 4Severe Lower Limb IschemiaMay 2027
RocheFaricimab
Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor
ANGPT2, VEGFAPhase 4Neovascular Age-related Macular Degeneration (nAMD); Wet Age-related Macular Degeneration; Diabetic Macular Edema; Macular Degeneration Choroidal Neovascularization …Sep 2027
Guangdong Provincial People's HospitalBrolucizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 4Diabetic Macular Edema–
Shanghai Eye Disease Prevention and Treatment CenterConbercept
Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor
VEGFA, VEGFB, PGF, VEGFCPhase 4Diabetic Macular Edema–
AbbVieABBV-RGX-314 (surabgene lomparvovec, RGX-314)
AAV8 vector containing a transgene for anti-VEGF Fab
VEGFAPhase 3AMD; Neovascular Age-related Macular Degeneration; Diabetic Retinopathy (DR); Neovascular Age-Related Macular Degeneration (nAMD) …Dec 2026
AstraZenecaBevacizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Hepatocellular Carcinoma; Advanced Ovarian Cancer; Hepatocellular Carcinoma (HCC); Keloids …Dec 2026
BiotheusPM8002
bispecific antibody targeting PD-L1 and VEGF
CD274, VEGFA, PDCD1LG2Phase 3SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm …Jan 2027
Regeneron PharmaceuticalsAflibercept
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 3Neovascular Age-Related Macular Degeneration; Diabetic Maculopathy; Diabetic Macular Edema (DME); Proliferative Diabetic Retinopathy (PDR) …Jan 2027
RocheRanibizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Neovascular Age-related Macular Degeneration (nAMD); Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Neovascular Age-Related Macular Degeneration …Feb 2027
Innovent Biologics (Suzhou)IBI302
Anti-VEGF monoclonal antibody
VEGFAPhase 3Neovascular Age-related Macular DegenerationFeb 2027
4D Molecular Therapeutics4D-150
AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s
VEGFA, VEGFC, VEGFR2Phase 3Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema …Mar 2027
JSC NextGenNeovasculgen®
Plasmid DNA encoding vascular endothelial growth factor A (VEGF-A)
VEGFAPhase 3Ulcer Foot; ICMar 2027
AkesoAK112 (Ivonescimab)
Dual PD-1/TIGIT bispecific antibody
PDCD1, VEGFAPhase 3Pancreatic Cancer; Non-Small Cell Lung Cancer; Platinum-sensitive Ovarian Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC)May 2027
Alvotech SwissAVT29
VEGF-A inhibitor (proposed aflibercept HD biosimilar)
VEGFAPhase 3Diabetic Macular EdemaJul 2027
RocheBevacizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Hepatocellular Carcinoma; Advanced Liver CancersJul 2027
AmgenABP 938
Anti-VEGF monoclonal antibody
VEGFAPhase 3Neovascular Age-related Macular DegenerationJul 2027
Outlook TherapeuticsBevacizumab (ONS-5010)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Age-Related Macular DegenerationDec 2027
Innostellar BiotherapeuticsLX102
AAV-based gene therapy encoding VEGF-trap (soluble VEGF receptor fusion protein)
VEGFAPhase 3Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular DegenerationMar 2028
Belfast Health and Social Care Trustbrolucizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Severe Diabetic Macular OedemaNov 2028
Shanghai Pulmonary Hospital, Shanghai, ChinaPD-L1/VEGF Bispecific Antibody (PM8002)
PD-L1 and VEGF dual-targeting bispecific antibody
CD274, VEGFAPhase 3Locally Advanced Non-Small Cell Lung CancerDec 2033
Prestige BiopharmaBevacizumab (HD204)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Lung Cancer–
Jiangsu Simcere PharmaceuticalENDOSTAR
Recombinant human endostatin; antiangiogenic agent and vascular endothelial growth factor
VEGFAPhase 3Malignant Pleural Effusion–
Shandong Suncadia MedicineBevacizumab (BP102)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Advanced Malignant TumourDec 2026
Shanghai Henlius BiotechBevacizumab (HLX04)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Metastatic Colorectal Cancer; Carcinoma, HepatocellularDec 2026
Second Affiliated Hospital, Zhejiang University, School of MedicinePD-1/VEGF dual antibody
PD-1 inhibitor and anti-VEGF antibody
PDCD1, VEGFA, CTLA4Phase 2GlioblastomaJan 2027
ARCAGY/ GINECO GROUPBevacizumab-Awwb (MVASI)
Anti-VEGF monoclonal antibody
VEGFAPhase 2Ovarian CancerFeb 2027
Jiangsu HengRui MedicineBevacizumab (BP102)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Lung CancerNov 2027
Sierra Eye AssociatesRGX-314 Dose 1
AAV8 vector encoding anti-VEGF Fab
VEGFAPhase 2Diabetic Macular EdemaDec 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineIvonescimab (AK112)
Bispecific monoclonal antibody targeting PD-1 and VEGF
PDCD1, VEGFAPhase 2Esophageal Squamous Cell CarcinomaDec 2027
Zhejiang Cancer HospitalEndostar
Recombinant human endostatin; anti-angiogenic agent targeting VEGF signaling
VEGFAPhase 2Nasopharyngeal CarcinomaJun 2028
Swiss Cancer InstituteIvonescimab
Bispecific PD-1/VEGF antibody
PDCD1, VEGFAPhase 2NSCLCJul 2028
PPD Development, LPbevacizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Acute Respiratory Distress Syndrome (ARDS)Jul 2028
Adverum BiotechnologiesADVM-022
AAV gene therapy expressing aflibercept (VEGF inhibitor)
VEGFAPhase 2Neovascular Age-related Macular DegenerationAug 2028
Suzhou Suncadia BiopharmaceuticalsBevacizumab (BP102)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Malignant Solid TumorsDec 2028
VA Office of Research and DevelopmentItraconazole
Cytochrome P450 51 inhibitor
SMO, AKT1, VEGFAPhase 2Esophageal AdenocarcinomaApr 2029
Koen RoversCAPOX-bevacizumab
Oxaliplatin and capecitabine with anti-VEGF monoclonal antibody
VEGFAPhase 2Colorectal NeoplasmJun 2029
Koen RoversFOLFIRI-bevacizumab
Irinotecan, 5-fluorouracil, and leucovorin with anti-VEGF monoclonal antibody
VEGFAPhase 2Colorectal NeoplasmJun 2029
Koen RoversFOLFOX-bevacizumab
Oxaliplatin, 5-fluorouracil, and leucovorin with anti-VEGF monoclonal antibody
VEGFAPhase 2Colorectal NeoplasmJun 2029
Ashvattha TherapeuticsAflibercept (D-4517)
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 2Neovascular Age-related Macular Degeneration–
Samsung BioepisAflibercept (SB15)
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 2Neovascular Age-related Macular Degeneration–
Chengdu Origen BiotechnologyKH631
AAV vector-based gene therapy expressing anti-VEGF protein
VEGFAPhase 1Age-Related Macular DegenerationDec 2026
Chengdu Origen BiotechnologyKH658
AAV vector delivering anti-VEGF protein
VEGFAPhase 1Age-related Macular Degeneration; Age-Related Macular DegenerationDec 2026
Avirmax BiopharmaABI-110
AAV2-delivered VEGF Trap
VEGFAPhase 1Neovascular (Wet) AMDJan 2027
OncoC4AI-081
Bispecific antibody targeting PD-1 and VEGF
PDCD1, VEGFAPhase 1Advanced Solid TumorJun 2027
Unlimited BiotechnologyVEGF Plasmid
Intramuscular plasmid DNA encoding vascular endothelial growth factor to induce angiogenes
VEGFAPhase 1Age-related Muscle DeclineSep 2027
Eyconis INC.EYC-0305
Anti-VEGF monoclonal antibody or VEGF-binding protein with extended-delivery formulation
VEGFAPhase 1Neovascular (Wet) Age-Related Macular DegenerationMay 2028
Jiangsu Simcere PharmaceuticalSIM0689 for Injection
PD-1/VEGF bispecific antibody
PDCD1, VEGFAPhase 1Neoplasms, MalignantDec 2028
Eli LillyAAVAnc80-antiVEGF
AAV-mediated anti-VEGF gene therapy
VEGFAPhase 1Vestibular SchwannomaAug 2029
AP BiosciencesAP505
Anti-PD-L1 and Anti-VEGF antibody fusion protein
CD274, VEGFAPhase 1Advanced Solid Tumors–
Institute of Automation, Chinese Academy of SciencesBev-ICG
VEGF-A targeting fluorescent probe (bevacizumab conjugated to indocyanine green)
VEGFAPhase 1Gastrointestinal Carcinoma–
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.IMM2510
Anti-PD-L1/VEGF bispecific antibody fusion protein
CD274, VEGFAPhase 1Advanced Solid Tumors–
Second Affiliated Hospital, Zhejiang University, School of MedicineIntrastromal anti-VEGF injection
Vascular Endothelial Growth Factor (VEGF) inhibition
VEGFAPhase 1Herpes Simplex Keratitis–
Lomonosov Moscow State University Medical Research and Educational CenterMediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparatio
Human mesenchymal stromal cell secretome containing vascular endothelial growth factor (VE
VEGFAPhase 1Azoospermia, Nonobstructive–

Conditions

Hepatocellular Carcinoma (22) Neovascular Age-related Macular Degeneration (11) Hepatocellular Carcinoma (HCC) (10) Colorectal Cancer (10) Metastatic Colorectal Cancer (9) Diabetic Macular Edema (8) Glioblastoma (7) Ovarian Cancer (7) Colorectal Cancer Metastatic (5) Lung Cancer (4) Neovascular Age-Related Macular Degeneration (4) Severe Diabetic Macular Oedema (4)

Modalities

antibody (19), small molecule (15), mixed (13), other (6), protein or peptide (1)

Companies

Roche (4) Second Affiliated Hospital, Zhejiang University, School of Medicine (3) Koen Rovers (3) Jiangsu Simcere Pharmaceutical (2) Chengdu Origen Biotechnology (2) Sierra Eye Associates (1) Biotheus (1) Amur State Medical Academy (1) Lomonosov Moscow State University Medical Research and Educational Center (1) AstraZeneca (1) Prestige Biopharma (1) Belfast Health and Social Care Trust (1) Institute of Automation, Chinese Academy of Sciences (1) Swiss Cancer Institute (1) Avirmax Biopharma (1) Eli Lilly (1) 4D Molecular Therapeutics (1) JSC NextGen (1) PPD Development, LP (1) Shanghai Henlius Biotech (1)

Related targets

PDCD1 (6) CD274 (4) PGF (4) VEGFC (2) ANGPT2 (2) PDCD1LG2 (1) VEGFR2 (1) VEGFB (1) CTLA4 (1) SMO (1) AKT1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.